RetroSense Therapeutics adds Dmitry Kuzmin to its Board along with securing $6m in Series B financing

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, MI – RetroSense Therapeutics, a privately-held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision. The investment syndicate includes existing investors, including BlueWater Angels, and new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical Co., Ltd.… => more

RetroSense Therapeutics adds Dmitry Kuzmin to its Board along with securing $6m in Series B financing

From:: RetroSense Therapeutics adds Dmitry Kuzmin to its Board along with securing $6m in Series B financing